----item----
version: 1
id: {564B541B-2C1E-47AE-98C7-7D05B07561AF}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/10/15/FDA Rejects Pfizers Xeljanz In Plaque Psoriasis
parent: {05EE13F4-80EE-4127-B996-2501E287FBE1}
name: FDA Rejects Pfizers Xeljanz In Plaque Psoriasis
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 663202f7-7f85-4a12-824f-b3f4fdc17f32

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 48

FDA Rejects Pfizer's Xeljanz In Plaque Psoriasis
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 47

FDA Rejects Pfizers Xeljanz In Plaque Psoriasis
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1522

<p>After the markets closed on Oct. 14, Pfizer Inc. disclosed the FDA had rejected the firm's supplemental new drug application (sNDA) for its JAK inhibitor Xeljanz (tofacitinib citrate) as a treatment for adults with moderate to severe chronic plaque psoriasis. </p><p>Pfizer did not reveal the details of the FDA's complete response letter but said the company would work with regulators to determine an appropriate path forward to address their comments, including providing additional safety analyses of Xeljanz for the proposed indication. </p><p>Xeljanz initially was approved for the US market in <a href="http://www.scripintelligence.com/home/Pfizers-Xeljanz-elected-in-US-as-1st-JAK-in-RA-336912" target="_new">November 2012</a> as a treatment for moderately to severely active rheumatoid arthritis who have had an inadequate response or are intolerant to methotrexate.</p><p>The small molecule medicine targets the JAK pathway, a signaling pathway inside the cells, thought to play a role in chronic inflammatory responses.</p><p>The sNDA in the plaque psoriasis indication was based on data from the firm's comprehensive Phase III "OPT" clinical development program, which consisted of five trials, including an ongoing long-term extension study, designed to evaluate oral Xeljanz 5mg and 10mg twice daily.</p><p>Psoriasis is a chronic, immune-mediated inflammatory skin disease, affecting the skin and other parts of the body, such as nails. It affects about 7.4 million people in the US.</p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 267

<p>After the markets closed on Oct. 14, Pfizer Inc. disclosed the FDA had rejected the firm's supplemental new drug application (sNDA) for its JAK inhibitor Xeljanz (tofacitinib citrate) as a treatment for adults with moderate to severe chronic plaque psoriasis. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 47

FDA Rejects Pfizers Xeljanz In Plaque Psoriasis
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151015T152034
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151015T152034
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151015T152034
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC030062
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 48

FDA Rejects Pfizer's Xeljanz In Plaque Psoriasis
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360976
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042507Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

663202f7-7f85-4a12-824f-b3f4fdc17f32
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042507Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
